Compare Gilead Sciences, Inc. (GILD) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Gilead Sciences, Inc. trades at $149 (market cap $182.40B), while Tripadvisor Inc Common Stock trades at $8.9 (market cap $1.01B). The key difference: Gilead Sciences, Inc. is far larger — about 180.6× Tripadvisor Inc Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| GILD | TRIP | |
|---|---|---|
Market Cap | $182.40B | $1.01B |
Volume | 4,469,821 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $16.72 |
52-Week Low | $116.74 | $8.04 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.46B | $1.06B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
TripAdvisor (TRIP) trades at $8.63, down 42% over the past year and near its 52-week low of $8.27. The stock shows bearish technical signals with recent earnings misses and declining revenue projections for 2026. Despite a low P/S ratio of 0.57, the company faces challenges from AI-driven competition eroding its core travel platform relevance.
The investment outlook remains cautious with analysts divided (21% Buy, 63% Hold) and a $13.58 price target suggesting 57% upside. Key risks include persistent search pressure, TheFork subsidiary sale execution, and competitive threats from AI travel tools. Positive cash flow from operations provides some stability amid the challenging transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
